News

Civica Appoints Dave Sehgal as Chief Manufacturing Officer and Supply Chain Officer

Civica announced the appointment of Dave Sehgal, Ph.D. as its new Chief Manufacturing Officer and Supply Chain Officer, effective July 21. In this role, Dr. Sehgal will lead Civica’s manufacturing strategy and operations, reporting directly to Ned McCoy, President and CEO.

“We are excited to welcome Dave to our leadership team,” said McCoy. “His deep expertise in pharmaceutical manufacturing and global operations will be instrumental as we continue to bring our Petersburg facility online and expand access to essential medicines.”

Sehgal has nearly 30 years of experience in the pharmaceutical industry, having held leadership roles in the vaccines, biologics and small molecule manufacturing space. He also has significant experience in technical services, quality and process development. Dr. Sehgal succeeds Jay Benson.

“I am thrilled to join Civica at this time in the company’s history,” said Sehgal. “I look forward to leading the team that will bring high-quality, essential generic medicines, manufactured in the United Sates to patients who need them.”

Dr. Sehgal resides in Raleigh, NC and will be working closely with the Civica team at the company’s manufacturing facility in Petersburg, Va. The 140,000 square foot, state-of-the-art facility currently employs more than 200 skilled workers, with plans to hire another 60 employees by the end of 2025. The facility has the capacity to manufacture 90 million vials, 50 million syringes and 120 million pre-filled pens of generic sterile injectable medicines every year. The facility is in the final stages of certification by regulatory authorities and will be producing medicines for distribution in 2026.

Prior to joining Civica, Dr. Sehgal was the Vice President and Global Processing Engineering Head at CSL-Behring in Holly Springs, North Carolina. In that role, he led a team of 500 scientists and engineers across four global sites in support of all CSL-Behring products. Before CSL-Behring, Sehgal held leadership positions at FUJIFILM Diosynth Biotechnologies, Seqirus, Novartis, and Merck. Sehgal earned a bachelor’s, master’s, and doctoral degree in chemical engineering from NC State University.

This appointment reflects Civica’s continued commitment to operational excellence and its mission to make quality generic medicines accessible and affordable for all.

 

Read more here.

Recent News

05/22/2026

BIO Statement on Veto of Prescription Drug Affordability Boards (PDAB) in VirginiaPatrick J. Plues, Senior Vice President of State Government Affairs & Affiliate Relations at the Biotechnology Innovation Organization (BIO) released the following statement on the veto of Prescription Drug Affordability Boards (PDAB) legislation in Virginia: “BIO applauds Governor Spanberger’s decision to veto SB 271 and HB 483 — legislation that would have established a Prescription Drug Affordability Board (PDAB) and imposed arbitrary price controls in Virginia. The Governor’s action recognized an important point: even well-intentioned healthcare policies must be carefully designed to avoid unintended consequences for patients, providers, employers, and Virginia’s innovation economy. “BIO is proud to represent biotechnology companies developing the next generation of life-changing medicines, including many in the Commonwealth. We believe policymakers play a critically important role in helping advance both patient access to treatments and the continued growth of the life sciences sector. “We look forward to working with the Governor’s Administration, the General Assembly, Virginia Bio and other stakeholders to advance practical, patient-centered policy solutions that improve affordability while preserving access to care and the innovation ecosystem patients depend on.”

Patrick J. Plues, Senior Vice President of State Government Affairs & Affiliate Relations at the Biotechnology Innovation Organization (BIO) released the following statement on the veto of Prescription Drug Affordability Boards (PDAB) legislation in Virginia: “BIO applauds Governor Spanberger’s decision to veto SB 271 and HB 483 — legislation that would have established a Prescription

05/21/2026

Virginia Bio Applauds Governor Spanberger’s Veto of SB 271 and HB 483

The Virginia Biotechnology Association (Virginia Bio) today expressed strong support for Governor Abigail Spanberger’s decision to veto Senate Bill 271 and House Bill 483, legislation that would have established a Prescription Drug Affordability Advisory Panel (PDAAP) in the Commonwealth. Virginia Bio and the Virginia Chamber of Commerce sent a joint letter to Governor Spanberger commending

05/21/2026

New Global Clinical Society to Bring Focused Ultrasound Into Mainstream Medicine

The Focused Ultrasound Foundation today announced the launch of the International Focused Ultrasound Society (IFUS), a new organization dedicated to advancing clinical practice and accelerating adoption of focused ultrasound – a revolutionary, noninvasive therapeutic technology. Established as a program of the Focused Ultrasound Foundation, IFUS aggregates and expands the Foundation’s activities related to clinical implementation